Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Sold by Whittier Trust Co. of Nevada Inc.

Whittier Trust Co. of Nevada Inc. trimmed its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.1% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 38,802 shares of the medical research company’s stock after selling 437 shares during the period. Whittier Trust Co. of Nevada Inc.’s holdings in Thermo Fisher Scientific were worth $24,002,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Stewardship Advisors LLC bought a new stake in shares of Thermo Fisher Scientific in the third quarter worth $267,000. Northwest Investment Counselors LLC bought a new position in shares of Thermo Fisher Scientific in the third quarter valued at approximately $194,000. Border to Coast Pensions Partnership Ltd lifted its holdings in shares of Thermo Fisher Scientific by 8.9% in the third quarter. Border to Coast Pensions Partnership Ltd now owns 83,608 shares of the medical research company’s stock valued at $51,566,000 after purchasing an additional 6,847 shares in the last quarter. James Hambro & Partners LLP grew its stake in Thermo Fisher Scientific by 5.7% in the third quarter. James Hambro & Partners LLP now owns 209,453 shares of the medical research company’s stock valued at $129,524,000 after purchasing an additional 11,276 shares in the last quarter. Finally, Castleview Partners LLC raised its holdings in shares of Thermo Fisher Scientific by 2.2% during the 3rd quarter. Castleview Partners LLC now owns 1,656 shares of the medical research company’s stock valued at $1,024,000 after purchasing an additional 36 shares in the last quarter. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Stock Performance

TMO traded down $7.00 during trading on Monday, reaching $594.71. 540,785 shares of the company’s stock were exchanged, compared to its average volume of 1,461,975. The company’s fifty day simple moving average is $607.99 and its 200-day simple moving average is $584.23. The stock has a market capitalization of $227.18 billion, a P/E ratio of 37.33, a price-to-earnings-growth ratio of 3.85 and a beta of 0.77. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.72 and a quick ratio of 1.37. Thermo Fisher Scientific Inc. has a 1 year low of $415.60 and a 1 year high of $627.88.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Wednesday, July 24th. The medical research company reported $5.37 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.13 by $0.24. The company had revenue of $10.54 billion during the quarter, compared to the consensus estimate of $10.50 billion. Thermo Fisher Scientific had a return on equity of 18.22% and a net margin of 14.69%. Thermo Fisher Scientific’s revenue for the quarter was down 1.4% on a year-over-year basis. During the same period in the previous year, the company posted $5.15 earnings per share. As a group, research analysts predict that Thermo Fisher Scientific Inc. will post 21.72 earnings per share for the current fiscal year.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 2,000 shares of the stock in a transaction on Friday, July 26th. The shares were sold at an average price of $600.85, for a total transaction of $1,201,700.00. Following the transaction, the senior vice president now directly owns 13,083 shares of the company’s stock, valued at $7,860,920.55. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In related news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction dated Wednesday, July 31st. The stock was sold at an average price of $617.21, for a total transaction of $6,172,100.00. Following the completion of the sale, the chief executive officer now directly owns 123,816 shares of the company’s stock, valued at approximately $76,420,473.36. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Michael A. Boxer sold 2,000 shares of Thermo Fisher Scientific stock in a transaction dated Friday, July 26th. The shares were sold at an average price of $600.85, for a total value of $1,201,700.00. Following the completion of the transaction, the senior vice president now owns 13,083 shares of the company’s stock, valued at $7,860,920.55. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 23,084 shares of company stock valued at $14,094,292. 0.34% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

TMO has been the topic of several recent analyst reports. TD Cowen lifted their price target on Thermo Fisher Scientific from $648.00 to $658.00 and gave the stock a “buy” rating in a research report on Thursday, July 25th. Morgan Stanley increased their price target on shares of Thermo Fisher Scientific from $655.00 to $680.00 and gave the stock an “overweight” rating in a research report on Friday, September 20th. Barclays upped their target price on shares of Thermo Fisher Scientific from $600.00 to $620.00 and gave the stock an “equal weight” rating in a report on Tuesday, October 15th. Royal Bank of Canada restated an “outperform” rating and issued a $767.00 price objective on shares of Thermo Fisher Scientific in a report on Friday, September 20th. Finally, Stifel Nicolaus boosted their target price on Thermo Fisher Scientific from $615.00 to $680.00 and gave the company a “buy” rating in a research note on Friday, September 20th. Four analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Thermo Fisher Scientific currently has a consensus rating of “Moderate Buy” and an average target price of $656.16.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.